<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203837</url>
  </required_header>
  <id_info>
    <org_study_id>STU000201854</org_study_id>
    <nct_id>NCT03203837</nct_id>
  </id_info>
  <brief_title>Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®</brief_title>
  <official_title>Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma
      patients who undergo radioembolization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have planned lobar radioembolization (TheraSphere (TS)) and consent to this
      study will have peripheral blood samples collected pre-TS, post-TS, 4 hours post-TS, 24 hours
      post-TS, 3 days post-TS, 7 days post-TS and 30 days post-TS to analyze specific angiogenic,
      inflammatory and immune profiles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in angiogenic, inflammatory and immune biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>The percent of change at 7 different timepoints for the following biomarkers will be calculated: Ang-2, FGFb, HB-EGF, HGF, PDGF-BB, PIGF, SDF-1, VEGF, VEGFC, IFNg, IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNFa trimer, CRP, TGFb1, EGFR, PD-1, PD-L1, CD45RA, CD127, HLA-DR, CD62L, CD3, CD8, CD197, CCR7, CD45RO, PD-L2, FOXP3, Perforin, Granzyme, TIA-1, CD14, CD107a, CD25, CD45, CD4, CD20 and CD56+16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Response- AFP</measure>
    <time_frame>2 years</time_frame>
    <description>Alphafetoprotein will be measured in ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response - Imaging</measure>
    <time_frame>2 years</time_frame>
    <description>Lesions will be measured using mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response- Time-to-Progression</measure>
    <time_frame>2 years</time_frame>
    <description>Time-to-progression will be measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response- Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival will be measured in days.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HCC patients</arm_group_label>
    <description>HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma collection</intervention_name>
    <description>We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.</description>
    <arm_group_label>HCC patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Any leftover patient plasma samples collected for this study will be retained for future
      research which may or may not involve genetic testing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with hepatocellular carcinoma who will be receiving lobar TheraSphere
        radioembolization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have the diagnosis of HCC (biopsy or imaging criteria)

          -  Must have planned lobar TheraSphere treatment

          -  Must be able to give consent

          -  Must have an ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2

          -  Must have a life expectancy of ≥ 3 months

          -  Women must not be pregnant with an acceptable contraception in premenopausal women

          -  Must be &gt; 4 weeks since prior radiation

          -  Must be &gt; 2 weeks since liver surgery

          -  Must be ≥ 2 weeks post radiosensitizing chemotherapy or &gt; 6 weeks since prior BCNU
             (carmustine) or Mitomycin-C

        Exclusion Criteria:

          -  Patients are excluded if they do not meet the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lewandowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlene del Castillo, RN</last_name>
    <phone>312-695-1518</phone>
    <email>carlene.castillo@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Lewandowski, MD</last_name>
    <phone>312-695-9121</phone>
    <email>r-lewandowski@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlene del Castillo, RN</last_name>
      <phone>312-695-1518</phone>
      <email>carlene.castillo@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Kulik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riad Salem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aparna Kalyan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001 Feb;233(2):227-35.</citation>
    <PMID>11176129</PMID>
  </reference>
  <reference>
    <citation>Ng IO, Lai EC, Fan ST, Ng MM, So MK. Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer. 1995 Dec 15;76(12):2443-8.</citation>
    <PMID>8625069</PMID>
  </reference>
  <reference>
    <citation>Finkenzeller G, Marmé D, Weich HA, Hug H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res. 1992 Sep 1;52(17):4821-3.</citation>
    <PMID>1511446</PMID>
  </reference>
  <reference>
    <citation>Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Ylä-Herttuala S, Risau W, Martin JF, Erusalimsky JD. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 1995 Jan 30;358(3):311-5.</citation>
    <PMID>7843420</PMID>
  </reference>
  <reference>
    <citation>Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007 Apr;43(6):979-92. Epub 2007 Feb 8. Review.</citation>
    <PMID>17291746</PMID>
  </reference>
  <reference>
    <citation>Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K, Monden M. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 2006 May;26(4):414-23.</citation>
    <PMID>16629644</PMID>
  </reference>
  <reference>
    <citation>Bassullu N, Turkmen I, Dayangac M, Yagiz Korkmaz P, Yasar R, Akyildiz M, Yaprak O, Tokat Y, Yuzer Y, Bulbul Dogusoy G. The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma. Hepat Mon. 2012 Oct;12(10 HCC):e7492. doi: 10.5812/hepatmon.7492. Epub 2012 Oct 11.</citation>
    <PMID>23162604</PMID>
  </reference>
  <reference>
    <citation>Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura N. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001 May 18;84(10):1377-83.</citation>
    <PMID>11355950</PMID>
  </reference>
  <reference>
    <citation>Tang Z, Qin L, Wang X, Zhou G, Liao Y, Weng Y, Jiang X, Lin Z, Liu K, Ye S. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl). 1998 Apr;111(4):313-8.</citation>
    <PMID>10374394</PMID>
  </reference>
  <reference>
    <citation>Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A, Grigioni WF. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003 May;35(5):332-8.</citation>
    <PMID>12846405</PMID>
  </reference>
  <reference>
    <citation>Lee TY, Kim KT, Han SY. Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver. Korean J Hepatol. 2007 Mar;13(1):70-80.</citation>
    <PMID>17380077</PMID>
  </reference>
  <reference>
    <citation>Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008 Jan 2;299(1):53-60. doi: 10.1001/jama.2007.65.</citation>
    <PMID>18167406</PMID>
  </reference>
  <reference>
    <citation>Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42. Review.</citation>
    <PMID>16493418</PMID>
  </reference>
  <reference>
    <citation>Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, Saito T, Togashi H, Kawata S. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 2004 Feb;24(1):21-8.</citation>
    <PMID>15101997</PMID>
  </reference>
  <reference>
    <citation>Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhör T, Peck-Radosavljevic M, Beug H, Mikulits W. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol. 2010 Jan;176(1):472-81. doi: 10.2353/ajpath.2010.090300. Epub 2009 Dec 11.</citation>
    <PMID>20008139</PMID>
  </reference>
  <reference>
    <citation>Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6.</citation>
    <PMID>9012848</PMID>
  </reference>
  <reference>
    <citation>Tada M, Kanai F, Tanaka Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Muroyama R, Fukai K, Imazeki F, Kawabe T, Yokosuka O, Omata M. Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res. 2008 Jun 15;14(12):3768-76. doi: 10.1158/1078-0432.CCR-07-1181.</citation>
    <PMID>18559595</PMID>
  </reference>
  <reference>
    <citation>Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol. 2007 Aug;31(2):451-60.</citation>
    <PMID>17611703</PMID>
  </reference>
  <reference>
    <citation>Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006 Jan 15;66(2):605-12. Review.</citation>
    <PMID>16423985</PMID>
  </reference>
  <reference>
    <citation>Talaat RM, Esmail AA, Elwakil R, Gurgis AA, Nasr MI. Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer. 2012 Jan;31(1):29-35. doi: 10.5732/cjc.011.10258. Epub 2011 Dec 23.</citation>
    <PMID>22200181</PMID>
  </reference>
  <reference>
    <citation>Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012 Dec;60(3):686-93. doi: 10.1016/j.cyto.2012.07.017. Epub 2012 Aug 18.</citation>
    <PMID>22906998</PMID>
  </reference>
  <reference>
    <citation>Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86.</citation>
    <PMID>1699862</PMID>
  </reference>
  <reference>
    <citation>Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996 May;8(5):765-72.</citation>
    <PMID>8671665</PMID>
  </reference>
  <reference>
    <citation>Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, Ferrari C. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006 Nov;80(22):11398-403. Epub 2006 Sep 6.</citation>
    <PMID>16956940</PMID>
  </reference>
  <reference>
    <citation>Wenjin Z, Chuanhui P, Yunle W, Lateef SA, Shusen Z. Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B. BMC Gastroenterol. 2012 Aug 16;12:109. doi: 10.1186/1471-230X-12-109.</citation>
    <PMID>22894700</PMID>
  </reference>
  <reference>
    <citation>Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, Wang H, Lou M, Wang FS, Lv JY, Yang YP. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6(9):e23621. doi: 10.1371/journal.pone.0023621. Epub 2011 Sep 1.</citation>
    <PMID>21912640</PMID>
  </reference>
  <reference>
    <citation>Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007 Apr;81(8):4215-25. Epub 2007 Feb 7.</citation>
    <PMID>17287266</PMID>
  </reference>
  <reference>
    <citation>Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, Cavallo MC, Orlandini A, Missale G, Ferrari C. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol. 2008 Apr;48(4):548-58. doi: 10.1016/j.jhep.2007.12.014. Epub 2008 Jan 28. Erratum in: J Hepatol. 2008 Sep;49(3):483.</citation>
    <PMID>18280607</PMID>
  </reference>
  <reference>
    <citation>Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014 May;63(5):844-55. doi: 10.1136/gutjnl-2013-306627. Epub 2014 Feb 14. Review.</citation>
    <PMID>24531850</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Robert Lewandowski</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Radioembolization</keyword>
  <keyword>Y90</keyword>
  <keyword>TheraSphere</keyword>
  <keyword>HCC</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Prognostic factor</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Inflammatory</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

